title: Biocompatibility of elastin-like polymer poly(VPAVG) microparticles: in vitro and in vivo studies.
abstract: Poly(L-valine-L-proline-L-alanine-L-valine-L-glycine) (VPAVG) is a new kind of proteinaceous polymer belonging to the Elastin-like family. These polymers are based on the recurrence of certain short peptide monomers that are considered as "building blocks" in the natural elastin. This smart thermoresponsive polymer has the ability to self-associate at physiological temperature to form aggregates with about 60% in water. This ability can be harnessed to prepare microparticles loaded with an active substance. The aim of this report is to evaluate, from the results of the experiment conducted, the biocompatibility of microparticles prepared from poly(VPAVG). We have studied the cytotoxic effects of microparticles, edema formation after subcutaneous injection (1 and 2.5 mg) in rats (n = 6), and also intraocular tolerance after the intravitreal injection of 2.5 mg of poly(VPAVG) microparticles into pigmented rabbits (n = 12). The polymer did not induce any cytotoxicity or nonspecific depression of cellular respiration on macrophages under the range of polymer concentrations investigated in this study (20, 30, 40, and 60 mg/mL). We observed no inflammatory response to microparticles after subcutaneous injection in the hind-paw of rats, with no significant differences between the control group (PBS) and experimental groups. Anterior and posterior segment signs were evaluated after intraocular injection of poly(VPAVG) microparticles. Only a few eyes (2/11) of the experimental group presented inflammation signs at day 28 postinjection. Nevertheless, 45% (5/11) of the eyes receiving microparticles showed tractional retinal detachment. The results observed in this work suggested certain fibroblastic activity induced by poly(VPAVG) microparticles after their intraocular injection.
authors.affiliation: Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, Complutense University, 28040 Madrid, Spain.
authors.forename: A C
authors.initials: AC
authors.lastname: Rincón
authors.forename: I T
authors.initials: IT
authors.lastname: Molina-Martinez
authors.forename: B
authors.initials: B
authors.lastname: de Las Heras
authors.forename: M
authors.initials: M
authors.lastname: Alonso
authors.forename: C
authors.initials: C
authors.lastname: Baílez
authors.forename: J C
authors.initials: JC
authors.lastname: Rodríguez-Cabello
authors.forename: R
authors.initials: R
authors.lastname: Herrero-Vanrell
mesh_terms: D000409:Alanine; D000595:Amino Acid Sequence; D000818:Animals; D001672:Biocompatible Materials; D002470:Cell Survival / Q000187:drug effects; D003231:Conjunctivitis / Q000517:prevention & control; D004487:Edema / Q000517:prevention & control; D004549:Elastin; D005998:Glycine; D017737:Macrophages, Peritoneal / Q000166:cytology* / Q000187:drug effects; D051379:Mice; D008855:Microscopy, Electron, Scanning; D008970:Molecular Weight; D010455:Peptides / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology*; D011392:Proline; D014633:Valine; D014822:Vitreous Body / Q000187:drug effects; D014961:X-Ray Diffraction
chemical_list: D001672:Biocompatible Materials; D010455:Peptides; D004549:Elastin; D011392:Proline; D014633:Valine; D000409:Alanine; D005998:Glycine